An experimental messenger RNA cancer vaccine developed jointly by Moderna and Merck has reduced the risk of melanoma recurrence or death by 42% in a late-stage clinical trial, according to data presented at the European Society for Medical Oncology Congress in Madrid.
Phase 3 INTerpath-001 Trial Results and Patient Outcomes
The Phase 3 INTerpath-001 trial evaluated 1,137 patients with high-risk melanoma whose tumors had been completely removed surgically. Two-thirds of the participants received multiple doses of the personalized mRNA therapy, designated as intismeran autogene, alongside the standard immunotherapy drug pembrolizumab, marketed as Keytruda. The remaining participants received pembrolizumab alone as a control group. Georgina Long, a medical oncologist at Melanoma Institute Australia and the University of Sydney who led the trial, reported that 82.2% of vaccinated patients were alive and had not relapsed after two years, compared to 70% in the control group.
Along with our partners at @Merck, we announced positive results from the Phase 3 INTerpath-001 study of intismeran autogene, our investigational individualized neoantigen therapy, in combination with pembrolizumab as adjuvant treatment in patients with completely resected Stage… pic.twitter.com/oaVDmxeHmx
The experimental treatment works by encoding dozens of neoantigen fragments from each patient’s cancer on a single strand, which prompts cells in the body to make the foreign-looking proteins and generate an immune response to them. Dr Gareth Rivalland, a medical oncologist and Melanoma New Zealand spokesperson, described the approach as combining traditional checkpoint inhibitors that unmasked cancer cells with a targeted mechanism to help the immune system identify rogue cells more precisely.
Commercial Hurdles and Regulatory Timeline Questions
Despite meeting its primary endpoint of recurrence-free survival, market analysts and researchers are evaluating the broader commercial viability and manufacturing costs of the personalized vaccine. Miguel Bronchud, a cancer clinician and researcher, noted that while the vaccine slashes the risk of return, the reason remains unclear. Financial analysts tracking the sector observed that traders adjusted positions following the data release, weighing the trial’s strong recurrence-free metrics against questions over distant metastasis benefits and eventual retail pricing.
In New Zealand, which shares with Australia the highest rates of melanoma in the world, around 40 patients participated in the global trial. Dr Rivalland stated that regulatory approval would depend on the complete dataset submitted by Moderna and Merck. Once approved, the primary barriers to patient access will involve manufacturing scale and cost.
Frequently Asked Questions About Intismeran Autogene
How does intismeran autogene differ from standard immunotherapy?
Standard immunotherapies like Keytruda are checkpoint inhibitors that encourage an antitumor immune response by blocking a protein on T cells. Intismeran autogene is a personalized vaccine tailored to an individual patient’s unique tumor, encoding up to 34 fragments of neoantigens identified in their cancers to train immune cells to target that specific cancer.
What specific trial metrics were reported in Madrid?
At the European Society for Medical Oncology Congress, trial lead Georgina Long reported that 82.2% of patients who received the vaccine were alive and had not relapsed after two years, compared to 70% in the control group receiving pembrolizumab alone.
When might the vaccine become available in New Zealand?
Local rollout depends on regulatory submissions by Moderna and Merck. Experts interviewed by New Scientist predict that some jurisdictions may approve the vaccine as soon as 2027, although timing remains uncertain and manufacturing costs could complicate access.
Worth a look